1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet

1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet


The Hepatitis C / HIV behemoth has seen its price tank in 2016 as investor fears about growth slowing -- and even reversing -- have come true. Slashing prices to maintain its Hepatitis C market share has dramatically impacted Gilead's top line, with overall revenue falling 9.6% year over year in the third quarter on a 30.7% decline in Hepatitis C revenue.



from Biotech News